imagen laboratorio

News and Events

News

La compostelana SunRock y el Instituto de Oncología del Vall d’Hebron reciben 1,8 millones de euros de la Agencia Estatal de Investigación para el desarrollo de nuevos anticuerpos en el tratamiento del cáncer de ovario

El consorcio integrado por SunRock Biopharma, con sede en el Biopolo Sionlla, y por VHIO lidera el proyecto OVERCAD,…

SunRock Biopharma will be giving an oral presentation on its anti-CCR9 antibody for IBD in ECCO25, Berlin.

SunRock’s communication has been selected for oral presentation at the 20th Congress of ECCO, February 19-22, 2025, Berlin, Germany. DOP065 SRB1:…

Debiopharm Extends SunRock Biopharma Partnership for Antibody Drug Conjugates Targeting HER3 in EGFR Mutated Cancers

Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today secured an…

Debiopharm and SunRock Biopharma Partner to Advance Antibody Drug Conjugates for Hard-to-Treat Cancers

September 21, 2023 Debiopharm to boost its ADC oncology pipeline through multi-asset partnership with SunRock’s antibody portfolio integrating Multilink™ & AbYlink™…

Research activity starts in Santiago at the Sionlla Biopolo with the installation of SunRock and Zinpro

The company from Santiago de Compostela is searching for antibodies against cancer, while the multinational is working on animal welfare. The…

SunRock Biopharma and VHIO are beneficiaries of a project funded with 1.7 million euros for the development of new antibodies for the treatment of solid tumors

The initiative aims to advance the development of new therapeutic options for breast cancer, colorectal cancer, and head and neck cancer….

SunRock Biopharma and IDIS secure 1.8 million euros in funding for the IMPANC project.

This initiative aims to advance the study of a new and effective therapeutic alternative that improves the lives of pancreatic cancer…

SunRock Biopharma receives the Bioga Award as a Competitive BioCompany

The company’s experience and trajectory in the development of cancer treatments have made SunRock worthy of this recognition. The Business Technology…

Ellipses Pharma and SunRock Biopharma enter into a licensing agreement for a first-in-class bifunctional HER3:TRAIL fusion protein

Ellipses Pharma granted exclusive global rights to develop and commercialise SRB22, in solid tumours   LONDON and SANTIAGO DE COMPOSTELA, Spain,…

Events

SunRock Biopharma, S.L will be attending the 20th Congress of ECCO European Crohn’ and Colitis Organisation in hashtag#Berlin from 19-22 February

We are a hashtag#biotech company with a pipeline of therapeutic hashtag#antibodies for the treatment of hashtag#inflammatory hashtag#bowel hashtag#disease. Are you attending…

Projects

IMPANC

TRADBI

Bonos de Innovación GAIN

DIAGBI

Itrapsens

Innovation Plan

Fartusomin

BiAbCan

Terperan

Axencia Galega de Innovación